Kainos Medicine, Inc. (KOSDAQ:284620)
South Korea · Delayed Price · Currency is KRW 1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025
Kainos Medicine Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,172 | 590.37 | 267.31 | 130.02 | 1,662 |
Other Revenue | - | - | - | -0 | - |
| 1,172 | 590.37 | 267.31 | 130.02 | 1,662 | |
Revenue Growth (YoY) | 98.46% | 120.85% | 105.59% | -92.18% | - |
Cost of Revenue | 1,001 | 199.88 | 90.71 | 68.11 | 38.61 |
Gross Profit | 170.35 | 390.48 | 176.6 | 61.91 | 1,624 |
Selling, General & Admin | 4,546 | 5,463 | 6,096 | 6,976 | 8,297 |
Research & Development | 1,277 | 5,645 | 9,519 | 7,931 | 3,685 |
Amortization of Goodwill & Intangibles | 207.88 | 341.52 | 266.31 | 509.68 | 210.73 |
Other Operating Expenses | 194.74 | 458.44 | 97.24 | 48.45 | 51.15 |
Operating Expenses | 7,034 | 12,893 | 16,988 | 16,218 | 12,843 |
Operating Income | -6,864 | -12,503 | -16,812 | -16,156 | -11,219 |
Interest Expense | -29.03 | -47.21 | -235.44 | -1,350 | -1,676 |
Interest & Investment Income | 114.07 | 397.04 | 617.54 | 418.58 | 91.57 |
Earnings From Equity Investments | -2,044 | -410.1 | 22.5 | - | - |
Currency Exchange Gain (Loss) | 30.52 | 126.47 | 38.01 | 136.85 | 10.83 |
Other Non Operating Income (Expenses) | 2,241 | 1,330 | 567.58 | -530.02 | -3,606 |
EBT Excluding Unusual Items | -6,551 | -11,107 | -15,801 | -17,481 | -16,399 |
Gain (Loss) on Sale of Investments | -4.53 | -719.32 | -65.12 | -535.81 | 125.76 |
Gain (Loss) on Sale of Assets | -21.46 | - | 628.33 | -32.01 | 48.87 |
Asset Writedown | -1,205 | -363 | - | - | - |
Other Unusual Items | - | - | - | 2,136 | - |
Pretax Income | -7,782 | -12,189 | -15,238 | -15,913 | -16,224 |
Income Tax Expense | 2.28 | 1.09 | 1.04 | 1.03 | 0.92 |
Earnings From Continuing Operations | -7,785 | -12,190 | -15,239 | -15,914 | -16,225 |
Minority Interest in Earnings | - | - | 4.22 | 32.95 | 13.84 |
Net Income | -7,785 | -12,190 | -15,235 | -15,881 | -16,212 |
Net Income to Common | -7,785 | -12,190 | -15,235 | -15,881 | -16,212 |
Shares Outstanding (Basic) | 32 | 28 | 28 | 24 | 21 |
Shares Outstanding (Diluted) | 32 | 28 | 28 | 24 | 21 |
Shares Change (YoY) | 13.70% | -0.33% | 17.14% | 12.49% | 4.59% |
EPS (Basic) | -246.00 | -438.00 | -545.62 | -666.22 | -765.00 |
EPS (Diluted) | -246.00 | -438.00 | -546.00 | -666.22 | -765.00 |
Free Cash Flow | -5,922 | -9,709 | -18,220 | -13,122 | -11,134 |
Free Cash Flow Per Share | -187.15 | -348.85 | -652.51 | -550.49 | -525.41 |
Gross Margin | 14.54% | 66.14% | 66.06% | 47.62% | 97.68% |
Operating Margin | -585.84% | -2117.82% | -6289.14% | -12425.09% | -674.87% |
Profit Margin | -664.43% | -2064.85% | -5699.35% | -12213.85% | -975.17% |
Free Cash Flow Margin | -505.48% | -1644.59% | -6815.87% | -10092.16% | -669.76% |
EBITDA | -6,273 | -11,351 | -15,535 | -14,893 | -10,410 |
D&A For EBITDA | 591.34 | 1,152 | 1,277 | 1,262 | 809.72 |
EBIT | -6,864 | -12,503 | -16,812 | -16,156 | -11,219 |
Advertising Expenses | - | - | 0.42 | 1.91 | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.